Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.

Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S.

Dig Dis Sci. 2018 Jun 9. doi: 10.1007/s10620-018-5144-y. [Epub ahead of print]

PMID:
29948562
2.

Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients.

Dutzer D, Nasser Y, Berger AE, Roblin X, Paul S.

Aliment Pharmacol Ther. 2018 Jun;47(11):1571-1573. doi: 10.1111/apt.14645. No abstract available.

PMID:
29878425
3.

Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.

Paul S, Williet N, Di Bernado T, Berger AE, Boschetti G, Filippi J, Del Tedesco E, Nancey S, Flourie B, Roblin X.

J Crohns Colitis. 2018 May 31. doi: 10.1093/ecco-jcc/jjy077. [Epub ahead of print]

PMID:
29860366
4.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Duffield AS, Ascierto ML, Anders RA, Taube JM, Meeker AK, Chen S, McMiller TL, Phillips NA, Xu H, Ogurtsova A, Berger AE, Pardoll DM, Topalian SL, Ambinder RF.

Blood Adv. 2017 Jul 21;1(17):1324-1334. doi: 10.1182/bloodadvances.2017007260. eCollection 2017 Jul 25.

5.

Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis.

Liu Q, Li D, Berger AE, Johns RA, Gao L.

Sci Rep. 2017 Sep 20;7(1):11957. doi: 10.1038/s41598-017-12289-4.

6.

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.

Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz GJ, Cottrell TR, Kohutek ZA, Favorov A, Makarov V, Riaz N, Chan TA, Cope L, Hruban RH, Pardoll DM, Taylor BS, Solit DB, Iacobuzio-Donahue CA, Topalian SL.

Clin Cancer Res. 2017 Jun 15;23(12):3168-3180. doi: 10.1158/1078-0432.CCR-17-0270. Epub 2017 Feb 13.

7.

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.

Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle C, Cope L, Drake CG, Pardoll DM, Taube JM, Topalian SL.

Cancer Immunol Res. 2016 Sep 2;4(9):726-33. doi: 10.1158/2326-6066.CIR-16-0072. Epub 2016 Aug 4.

8.

Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing.

Gao L, Emond MJ, Louie T, Cheadle C, Berger AE, Rafaels N, Vergara C, Kim Y, Taub MA, Ruczinski I, Mathai SC, Rich SS, Nickerson DA, Hummers LK, Bamshad MJ, Hassoun PM, Mathias RA; National Heart, Lung, and Blood Institute GO Exome Sequencing Project, Barnes KC.

Arthritis Rheumatol. 2016 Jan;68(1):191-200. doi: 10.1002/art.39449.

9.

Mobilization of epithelial mesenchymal transition genes distinguishes active from inactive lesional tissue in patients with ulcerative colitis.

Zhao X, Fan J, Zhi F, Li A, Li C, Berger AE, Boorgula MP, Barkataki S, Courneya JP, Chen Y, Barnes KC, Cheadle C.

Hum Mol Genet. 2015 Aug 15;24(16):4615-24. doi: 10.1093/hmg/ddv192. Epub 2015 Jun 1.

PMID:
26034135
10.

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.

Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, Berger AE, Pardoll DM, Topalian SL.

Clin Cancer Res. 2015 Sep 1;21(17):3969-76. doi: 10.1158/1078-0432.CCR-15-0244. Epub 2015 May 5.

11.

RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.

Langdon JM, Barkataki S, Berger AE, Cheadle C, Xue QL, Sung V, Roy CN.

Am J Hematol. 2015 Jan;90(1):8-14. doi: 10.1002/ajh.23856. Epub 2014 Oct 25.

12.

A genome-wide survey of CD4(+) lymphocyte regulatory genetic variants identifies novel asthma genes.

Sharma S, Zhou X, Thibault DM, Himes BE, Liu A, Szefler SJ, Strunk R, Castro M, Hansel NN, Diette GB, Vonakis BM, Adkinson NF Jr, Avila L, Soto-Quiros M, Barraza-Villareal A, Lemanske RF Jr, Solway J, Krishnan J, White SR, Cheadle C, Berger AE, Fan J, Boorgula MP, Nicolae D, Gilliland F, Barnes K, London SJ, Martinez F, Ober C, Celedón JC, Carey VJ, Weiss ST, Raby BA.

J Allergy Clin Immunol. 2014 Nov;134(5):1153-62. doi: 10.1016/j.jaci.2014.04.011. Epub 2014 Jun 13.

13.

Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension.

Yamaji-Kegan K, Takimoto E, Zhang A, Weiner NC, Meuchel LW, Berger AE, Cheadle C, Johns RA.

Am J Physiol Lung Cell Mol Physiol. 2014 Jun 15;306(12):L1090-103. doi: 10.1152/ajplung.00279.2013. Epub 2014 May 2.

14.

Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells.

McCranor BJ, Kim MJ, Cruz NM, Xue QL, Berger AE, Walston JD, Civin CI, Roy CN.

Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):126-33. doi: 10.1016/j.bcmd.2013.09.004. Epub 2013 Oct 9. Erratum in: Blood Cells Mol Dis. 2014 Apr;52(4):236.

15.

Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age.

McCranor BJ, Langdon JM, Prince OD, Femnou LK, Berger AE, Cheadle C, Civin CI, Kim A, Rivera S, Ganz T, Vaulont S, Xue QL, Walston JD, Roy CN.

Haematologica. 2013 Oct;98(10):1633-40. doi: 10.3324/haematol.2013.087114. Epub 2013 Aug 30.

16.

Modeling low-dose mortality and disease incubation period of inhalational anthrax in the rabbit.

Gutting BW, Marchette D, Sherwood R, Andrews GA, Director-Myska A, Channel SR, Wolfe D, Berger AE, Mackie RS, Watson BJ, Rukhin A.

J Theor Biol. 2013 Jul 21;329:20-31. doi: 10.1016/j.jtbi.2013.03.020. Epub 2013 Apr 6.

PMID:
23567649
17.

Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases.

Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, Baer AN, Rosen A.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17609-14. doi: 10.1073/pnas.1209724109. Epub 2012 Oct 8.

18.

Inhalational anthrax (Ames aerosol) in naïve and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremia.

Gutting BW, Nichols TL, Channel SR, Gearhart JM, Andrews GA, Berger AE, Mackie RS, Watson BJ, Taft SC, Overheim KA, Sherwood RL.

Front Cell Infect Microbiol. 2012 Jun 28;2:87. doi: 10.3389/fcimb.2012.00087. eCollection 2012.

19.

Late stage erythroid precursor production is impaired in mice with chronic inflammation.

Prince OD, Langdon JM, Layman AJ, Prince IC, Sabogal M, Mak HH, Berger AE, Cheadle C, Chrest FJ, Yu Q, Andrews NC, Xue QL, Civin CI, Walston JD, Roy CN.

Haematologica. 2012 Nov;97(11):1648-56. doi: 10.3324/haematol.2011.053397. Epub 2012 May 11.

20.

Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients.

Cheadle C, Berger AE, Mathai SC, Grigoryev DN, Watkins TN, Sugawara Y, Barkataki S, Fan J, Boorgula M, Hummers L, Zaiman AL, Girgis R, McDevitt MA, Johns RA, Wigley F, Barnes KC, Hassoun PM.

PLoS One. 2012;7(4):e34951. doi: 10.1371/journal.pone.0034951. Epub 2012 Apr 24.

21.

Tight junction defects in patients with atopic dermatitis.

De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA.

J Allergy Clin Immunol. 2011 Mar;127(3):773-86.e1-7. doi: 10.1016/j.jaci.2010.10.018. Epub 2010 Dec 15.

22.

Transcription of proteinase 3 and related myelopoiesis genes in peripheral blood mononuclear cells of patients with active Wegener's granulomatosis.

Cheadle C, Berger AE, Andrade F, James R, Johnson K, Watkins T, Park JK, Chen YC, Ehrlich E, Mullins M, Chrest F, Barnes KC, Levine SM.

Arthritis Rheum. 2010 Jun;62(6):1744-54. doi: 10.1002/art.27398.

23.

Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii.

Watford WT, Hissong BD, Durant LR, Yamane H, Muul LM, Kanno Y, Tato CM, Ramos HL, Berger AE, Mielke L, Pesu M, Solomon B, Frucht DM, Paul WE, Sher A, Jankovic D, Tsichlis PN, O'Shea JJ.

J Exp Med. 2008 Nov 24;205(12):2803-12. doi: 10.1084/jem.20081461. Epub 2008 Nov 10.

24.

Characterization of ciliated bronchial epithelium 1, a ciliated cell-associated gene induced during mucociliary differentiation.

Yoshisue H, Puddicombe SM, Wilson SJ, Haitchi HM, Powell RM, Wilson DI, Pandit A, Berger AE, Davies DE, Holgate ST, Holloway JW.

Am J Respir Cell Mol Biol. 2004 Nov;31(5):491-500. Epub 2004 Jul 8.

PMID:
15242845
25.

First human studies with a high-molecular-weight iron chelator.

Dragsten PR, Hallaway PE, Hanson GJ, Berger AE, Bernard B, Hedlund BE.

J Lab Clin Med. 2000 Jan;135(1):57-65.

PMID:
10638695
26.

Dual processing of two-dimensional exchange data in magic angle spinning NMR of solids.

Tycko R, Berger AE.

J Magn Reson. 1999 Nov;141(1):141-7.

PMID:
10527751
27.

Expression of interleukin-1 receptor antagonist protein in post-mortem human brain tissues of Alzheimer's disease and control cases.

Yasuhara O, Matsuo A, Terai K, Walker DG, Berger AE, Akiguchi I, Kimura J, McGeer PL.

Acta Neuropathol. 1997 Apr;93(4):414-20.

PMID:
9113207
28.

The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice.

Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND.

Arthritis Rheum. 1993 Sep;36(9):1305-14.

PMID:
8216424
29.

Regulation of expression of IL-1 receptor antagonist protein in human synovial and dermal fibroblasts.

Krzesicki RF, Hatfield CA, Bienkowski MJ, McGuire JC, Winterrowd GE, Chapman DL, Berger AE, McEwan RN, Carter DB, Chosay JG, et al.

J Immunol. 1993 May 1;150(9):4008-18.

PMID:
8473746
30.

Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist.

Wahl SM, Costa GL, Corcoran M, Wahl LM, Berger AE.

J Immunol. 1993 Apr 15;150(8 Pt 1):3553-60.

PMID:
8468489
31.

Cytokine regulation of the interleukin-1 receptor antagonist protein in U937 cells.

Berger AE, Carter DB, Hankey SO, McEwan RN.

Eur J Immunol. 1993 Jan;23(1):39-45.

PMID:
8419185
32.

Modulation of T lymphocyte function by the angiogenesis inhibitor AGM-1470.

Berger AE, Dortch KA, Staite ND, Mitchell MA, Evans BR, Holm MS.

Agents Actions. 1993;39 Spec No:C86-8.

PMID:
8273596
33.

Interleukin-1 receptor antagonist in normal and psoriatic epidermis.

Hammerberg C, Arend WP, Fisher GJ, Chan LS, Berger AE, Haskill JS, Voorhees JJ, Cooper KD.

J Clin Invest. 1992 Aug;90(2):571-83.

34.

IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium.

Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM, Yu C, Zvaifler NJ.

J Immunol. 1992 Aug 1;149(3):1054-62.

PMID:
1386092
35.

Sandwich ELISA formats designed to detect 17 kDa IL-1 beta significantly underestimate 35 kDa IL-1 beta.

Herzyk DJ, Berger AE, Allen JN, Wewers MD.

J Immunol Methods. 1992 Apr 8;148(1-2):243-54.

PMID:
1564329
36.
37.

Purification and characterization of interleukin 1 receptor level antagonist proteins from THP-1 cells.

Bienkowski MJ, Eessalu TE, Berger AE, Truesdell SE, Shelly JA, Laborde AL, Zurcher-Neely HA, Reardon IM, Heinrikson RL, Chosay JG, et al.

J Biol Chem. 1990 Aug 25;265(24):14505-11.

38.

Correlation of leukocyte interleukin-1 production with the stimulation of prostaglandin and tissue factor synthesis by human umbilical vein endothelial cells.

Schaub RG, Dunn CJ, Deibel MR, Berger AE, Wunderlich D, Fleming WE.

Agents Actions. 1990 Aug;31(1-2):127-34.

PMID:
2285018
39.

Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Carter DB, Deibel MR Jr, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, Berger AE, Bienkowski MJ, Sun FF, McEwan RN, et al.

Nature. 1990 Apr 12;344(6267):633-8.

PMID:
2139180
41.

Soybean trypsin inhibitor. An IL-1-like protein?

Richard KA, Speziale SC, Staite ND, Berger AE, Deibel MR Jr, Finzel BC, Einspahr HM.

Agents Actions. 1989 Jun;27(3-4):265-7.

PMID:
2801308
42.

Ferrioxamine as a magnetic resonance contrast agent. Preclinical studies and phase I and II human clinical trials.

Worah D, Berger AE, Burnett KR, Cockrill HH, Kanal E, Kendall C, Leese PT, Lyons KP, Ross E, Wolf GL, et al.

Invest Radiol. 1988 Sep;23 Suppl 1:S281-5.

PMID:
3058632
43.

Phosphorylation of a Mr 70,000 protein is associated with interleukin 2 receptor expression.

Swift AM, Davidson SO, Berger AE.

J Biol Chem. 1988 Feb 15;263(5):2389-96.

44.

Ethylnitrosourea treatment increases lectin binding to mouse germ cells.

Holm MS, Berger AE, Swanson K, Ficsor G, Ginsberg LC.

Toxicology. 1987 Nov;46(3):281-94.

PMID:
2445052
45.

Effect of trypsinization on lectin binding to germ cells from ICR and T/t6 mice.

Holm MS, Berger AE, Swanson K, Ginsberg LC.

Biol Reprod. 1987 Sep;37(2):282-7.

PMID:
3676386
48.

Preferential generation of human T cell hybrids with a tetraploid fusion partner.

Berger AE, Kuentzel SL, Davidson SO.

J Immunol. 1985 Sep;135(3):1792-9.

PMID:
3874906
49.

Comparative structural analysis of HLA-A3 antigens distinguishable by cytotoxic T lymphocytes: variant E1.

van Schravendijk MR, Biddison WE, Berger AE, Coligan JE.

J Immunol. 1985 Jan;134(1):410-6.

PMID:
3871112
50.

Etodolac, aspirin, and gastrointestinal microbleeding.

Arnold JD, Mullane JF, Hayden DM, March L, Hart K, Perdomo CA, Fencik M, Berger AE.

Clin Pharmacol Ther. 1984 May;35(5):716-21.

PMID:
6232035

Supplemental Content

Loading ...
Support Center